As a cancer vaccine vector, a Phase I trial evaluated alphavirus vectors expressing the carcinoembryonic antigen (CEA) in patients with advanced pancreatic cancer [49]. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.